# US 2023/0263731 A1 · Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0263731 A1
- Document ID: US20230263731A1
- Status: Published application
- Kind: A1
- Application number: 18/154,419
- Filed: 2023-01-13
- Published: 2023-08-24
- Earliest claimed: 2017-10-03
- Assignees: Crititech, Inc.
- Applicants: Crititech, Inc.
- Inventors: Gere S. DIZEREGA; Michael BALTEZOR; Sam CAMPBELL; Charles J. DECEDUE; Matthew MCCLOREY
- Web page: https://patentgrep.com/patent/US20230263731A1

## CPC

- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 2039/54: {characterised by the route of administration}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, arid intracystic injection.

## Claims

### Claim at position 1

-133. (canceled)

### Claim 134

A method of treating cancer in a subject, the method comprising:
(a) administering a first composition comprising taxane particles to a subject having a tumor, wherein the taxane particles comprise paclitaxel particles, docetaxel particles, cabazitaxel particles, or combinations thereof, wherein the taxane particles comprise at least 95% of the taxane, and wherein the taxane particles have a specific surface area (SSA) of at least 18 m2/g, and
(b) systemically administering a second composition comprising an immunotherapeutic agent to the subject, wherein the immunotherapeutic agent comprises an immune checkpoint inhibitor,
thereby treating the cancer, wherein the taxane particles have a mean particle size (number) of from 0.1 microns to 5 microns, and wherein steps (a) and (b) can be conducted in any order or at the same time.

### Claim 135 (depends on 134)

The method of claim 134, wherein the tumor is a malignant tumor.

### Claim 136 (depends on 134)

The method of claim 134, wherein the tumor comprises a lung tumor, sarcoma, a carcinoma, a lymphoma, a breast tumor, a prostate tumor, a head and neck tumor, a glioblastoma, a bladder tumor, a pancreatic tumor, a liver tumor, an ovarian tumor, a colorectal tumor, a skin tumor, an intraperitoneal organ tumor, a cutaneous metastasis, a lymphoid, and/or a gastrointestinal tumor.

### Claim 137 (depends on 134)

The method of claim 134, wherein the immune checkpoint inhibitor is selected from the group consisting of ipilimumab, pembrolizumab and nivolumab.

### Claim 138 (depends on 134)

The method of claim 134, wherein the taxane particles have a mean particle size (number) of from 0.1 microns to 1.5 microns.

### Claim 139 (depends on 134)

The method of claim 134, wherein the taxane particles are paclitaxel particles.

### Claim 140 (depends on 139)

The method of claim 139, wherein the paclitaxel particles have a bulk density (not-tapped) of 0.05 g/cm3 to 0.15 g/cm3.

### Claim 141 (depends on 134)

The method of claim 134, wherein the taxane particles are docetaxel particles.

### Claim 142 (depends on 141)

The method of claim 141, wherein the docetaxel particles have a bulk density (not-tapped) of 0.05 g/cm3 to 0.15 g/cm3.

### Claim 143 (depends on 134)

The method of claim 134, wherein the administering comprises topical administration, pulmonary administration, or intraperitoneal injection of the first composition to the subject.

### Claim 144 (depends on 134)

The method of claim 134 wherein the concentration of the taxane particles in the first composition is between about 1 mg/ml and about 40 mg/ml, or between about 6 mg/mL and about 20 mg/mL.

### Claim 145 (depends on 134)

The method of claim 134, wherein the first composition does not contain a protein.

### Claim 146 (depends on 134)

The method of claim 134, wherein the second composition comprises a pharmaceutically acceptable carrier.

### Claim 147 (depends on 134)

The method of claim 134, wherein the systemic administration is intravenous (IV) injection or oral delivery.
